Naresh Babu Muppalaneni

Computational Study on Protein-ligand Interactions for Anti-diabetic: in Silico Study Naresh Babu Muppalaneni

India is a world capital of diabetes, hence it is required immediate attention of drug design and development of novel drug. Though Type 2 Diabetes has many drugs, it lacks 100% effective cure. Drug design is mainly based on protein-ligand interactions and the active site residues. Advances in computational techniques have enabled virtual screening to have a positive impact on the discovery process. In ligand-based virtual screening, the strategy is to use information provided by a compound or set of compounds that are known to bind to the desired target and to use this to identify other compounds in the corporate database or external databases with similar properties. Most effective ligand binding to the protein can be known by this database which makes the drug design effective and easy.